MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
- PMID:31289443
- PMCID: PMC6563714
- DOI: 10.2147/OTT.S172315
MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
Abstract
Acute myeloid leukemia (AML) is a clonal heterogenous malignancy of the myeloid cells with a poor prognosis lending itself to novel treatment strategies. TP53 is a critical tumor suppressor and plays an essential role in leukemogenesis. Although TP53 is relatively unusual in de novo AML, inactivation of wild-type p53 (WT-p53) is a common event. Murine double minute 2 (MDM2) is a key negative regulator of p53 and its expression; inhibition of MDM2 is postulated to reactivate WT-p53 and its tumor suppressor functions. Nutlins were the first small molecule inhibitors that bind to MDM2 and target its interaction with p53. RG7388 (idasanutlin), a second-generation nutlin, was developed to improve upon the potency and toxicity profile of earlier nutlins. Preliminary data from early phase trials and ongoing studies suggest clinical response with RG7388 (idasanutlin) both in monotherapy and combination strategies in AML. We herein briefly discuss currently approved therapies in AML and review the clinical data for RG7388 (idasanutlin) and MDM2 inhibition as novel treatment strategies in AML. We further describe efficacy and toxicity profile data from completed and ongoing trials of RG7388 (idasanutlin) and other MDM2-p53 inhibitors in development. Many targeted therapies have been approved recently in AML, with a focus on the older and unfit population for intensive induction therapy and in relapsed/refractory disease. The "nutlins", including RG7388 (idasanutlin), merit continued investigation in such settings.
Keywords: AML; MDM2; RG7388; idasanutlin; myeloid leukemia; nutlins; p53 inhibitor.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Similar articles
- Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells.Skalniak L, Kocik J, Polak J, Skalniak A, Rak M, Wolnicka-Glubisz A, Holak TA.Skalniak L, et al.Cancers (Basel). 2018 Oct 24;10(11):396. doi: 10.3390/cancers10110396.Cancers (Basel). 2018.PMID:30352966Free PMC article.
- The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.Seipel K, Marques MAT, Sidler C, Mueller BU, Pabst T.Seipel K, et al.Cancers (Basel). 2018 May 31;10(6):170. doi: 10.3390/cancers10060170.Cancers (Basel). 2018.PMID:29857559Free PMC article.
- Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.Lehmann C, Friess T, Birzele F, Kiialainen A, Dangl M.Lehmann C, et al.J Hematol Oncol. 2016 Jun 28;9(1):50. doi: 10.1186/s13045-016-0280-3.J Hematol Oncol. 2016.PMID:27353420Free PMC article.
- Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists.Kocik J, Machula M, Wisniewska A, Surmiak E, Holak TA, Skalniak L.Kocik J, et al.Cancers (Basel). 2019 Jul 19;11(7):1014. doi: 10.3390/cancers11071014.Cancers (Basel). 2019.PMID:31331108Free PMC article.Review.
- MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation.Pellot Ortiz KI, Rechberger JS, Nonnenbroich LF, Daniels DJ, Sarkaria JN.Pellot Ortiz KI, et al.Biomedicines. 2023 Jul 2;11(7):1879. doi: 10.3390/biomedicines11071879.Biomedicines. 2023.PMID:37509518Free PMC article.Review.
Cited by
- The Correlation of Mouse Double Minute 4 (MDM4) Polymorphisms (rs4245739, rs1563828, rs11801299, rs10900598, and rs1380576) with Cancer Susceptibility: A Meta-Analysis.Chen J, Li X, Liu R, Xie Y, Liu Z, Xiong H, Li Y.Chen J, et al.Med Sci Monit. 2022 Mar 29;28:e935671. doi: 10.12659/MSM.935671.Med Sci Monit. 2022.PMID:35347102Free PMC article.
- Regulating tumor suppressor genes: post-translational modifications.Chen L, Liu S, Tao Y.Chen L, et al.Signal Transduct Target Ther. 2020 Jun 10;5(1):90. doi: 10.1038/s41392-020-0196-9.Signal Transduct Target Ther. 2020.PMID:32532965Free PMC article.Review.
- Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development.Stanchina M, Soong D, Zheng-Lin B, Watts JM, Taylor J.Stanchina M, et al.Cancers (Basel). 2020 Nov 1;12(11):3225. doi: 10.3390/cancers12113225.Cancers (Basel). 2020.PMID:33139625Free PMC article.Review.
- Current insights into the regulation of programmed cell death by TP53 mutation in cancer.Su Y, Sai Y, Zhou L, Liu Z, Du P, Wu J, Zhang J.Su Y, et al.Front Oncol. 2022 Oct 13;12:1023427. doi: 10.3389/fonc.2022.1023427. eCollection 2022.Front Oncol. 2022.PMID:36313700Free PMC article.Review.
- Exploiting Extracellular Vesicles Strategies to Modulate Cell Death and Inflammation in COVID-19.Bortot B, Romani A, Ricci G, Biffi S.Bortot B, et al.Front Pharmacol. 2022 May 20;13:877422. doi: 10.3389/fphar.2022.877422. eCollection 2022.Front Pharmacol. 2022.PMID:35668941Free PMC article.
References
- Acute Myeloid Leukemia-Cancer Stat Facts. [Accessed October 2, 2018]. Available from:https://seer.cancer.gov/statfacts/html/amyl.html.
Publication types
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous